# US 2024/0026437 A1 · Assessing transplant complication risk with total cell-free dna

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0026437 A1
- Document ID: US20240026437A1
- Status: Published application
- Kind: A1
- Application number: 18/343,097
- Filed: 2023-06-28
- Published: 2024-01-25
- Earliest claimed: 2017-06-20
- Assignees: The Medical College of Wisconsin, Inc.
- Applicants: The Medical College of Wisconsin Inc.
- Inventors: Aoy Tomita Mitchell; Michael Mitchell
- Web page: https://patentgrep.com/patent/US20240026437A1

## CPC

- C12Q 1/6858: Allele-specific amplification
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6851: Quantitative amplification
- C12Q 2535/101: Sanger sequencing method, i.e. oligonucleotide sequencing using primer elongation and dideoxynucleotides as chain terminators
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

This invention relates to methods and compositions for assessing an amount of total cell-free DNA, such as from a transplant subject. The methods and composition provided herein can be used to determine risk of complications following transplantation, including infection, cardiac arrest, and death, in a subject.

## Claims

### Claim 1

A method of assessing a sample from a transplant subject, the method comprising:
(a) determining an amount of total cf-DNA in a sample from the subject, wherein the subject has, is suspected of having, has had, or is at risk of having a transplant complication; and
(b) reporting and/or recording the amount of total cf-DNA.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method further comprises:
(c) comparing the amount of total cf-DNA to a threshold total cf-DNA value or at least one prior total cf-DNA amount.

### Claim 3 (depends on 1)

The method of claim 1, wherein the method further comprises:
(d) determining that the subject has, or as being at increased risk of having, a transplant complication based on the determined amount of total cf-DNA compared to the threshold total cf-DNA value and/or at least one prior total cf-DNA amount.

### Claim 4

A method of assessing a transplant subject, the method comprising:
(a) obtaining an amount of total cf-DNA in a sample from the subject, wherein the subject has, is suspected of having, has had, or is at risk of having a transplant complication;
(b) comparing the amount of total cf-DNA to a threshold total cf-DNA value and/or at least one prior total cf-DNA amount; and
(c) determining a treatment or monitoring regimen for the subject based on the determined amount of total cf-DNA compared to the threshold total cf-DNA value and/or at least one prior total cf-DNA amount.

### Claim 5 (depends on 4)

The method of claim 4, wherein the method further comprises classifying the subject as having or as being at increased risk of having a transplant complication based on the determined amount of total cf-DNA compared to the threshold total cf-DNA value and/or at least one prior total cf-DNA amount.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject is on or is in need of mechanical support.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject has been determined to have a transplant complication.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject was determined to have the transplant complication with one or more additional test(s) prior applied to the subject or the method further comprises performing one or more additional test(s) on the subject.

### Claim at position 9

9-14. (canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein the amount of total cf-DNA is determined or obtained by:
(a) for a plurality of single nucleotide variant (SNV) targets, performing an amplification-based quantification assay, such as a polymerase chain reaction (PCR) quantification assay, on the sample, or a portion thereof, with at least two primer pairs, wherein each primer pair comprises a forward primer and a reverse primer, wherein one of the at least two primer pairs comprises a 3′ penultimate mismatch in a primer relative to one allele of the SNV target, but a 3′ double mismatch relative to another allele of the SNV target and specifically amplifies the one allele of the SNV target, and another of the at least two primer pairs specifically amplifies to another allele of the SNV target, and (b) assessing the amount of total cf-DNA based on the results.

### Claim 16 (depends on 15)

The method of claim 15, wherein the genotype of the donor is known or unknown.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The method of claim 1, wherein the amount of total cf-DNA is determined or obtained using an amplification-based quantification assay.

### Claim at position 14

19-20. (canceled)

### Claim 21 (depends on 1)

The method of claim 1, wherein an amount of total cf-DNA of 8 or 9 ng/mL or greater represents a risk of cardiac arrest or death.

### Claim 22 (depends on 1)

The method of claim 1, wherein an amount of total cf-DNA of 20 ng/mL or greater represents the presence of an infection or an increased risk of infection.

### Claim 23 (depends on 1)

The method of claim 1, wherein at least one amount is determined in a sample taken from the subject within 4, 5, 6, 7, or 8 days following an organ transplant.

### Claim 24 (depends on 1)

The method of claim 1, wherein an amount of total cf-DNA that is greater than the threshold value and/or is increased relative to the amount from an earlier time point represents an increased or increasing risk, or wherein an amount of total cf-DNA that is lower than the threshold value and/or is decreased relative to the amount from an earlier time point represents a decreased or decreasing risk.

### Claim 25

(canceled)

### Claim 26 (depends on 4)

The method of claim 4, wherein the determining a monitoring regimen comprises determining the amount of total cf-DNA in the subject over time or at a subsequent point in time, suggesting such monitoring to the subject, or using or suggesting the use of one or more additional test(s) to assess the subject.

### Claim at position 21

27-33. (canceled)

### Claim 34 (depends on 4)

The method of claim 4, wherein the determining a treatment regimen comprises selecting or suggesting a treatment for the subject suggesting a treatment for the subject, treating the subject, or providing information about treatment to the subject.

### Claim at position 23

35-37. (canceled)

### Claim 38 (depends on 4)

The method of claim 4, wherein the treatment is an anti-infection treatment, an anti-rejection treatment, or a cardiac arrest treatment.

### Claim at position 25

39-40. (canceled)

### Claim 41 (depends on 1)

The method of claim 1, wherein the sample is a blood, plasma or serum sample.

### Claim 42

(canceled)

### Claim 43 (depends on 1)

The method of claim 1, wherein the transplant subject is a heart transplant subject.
